Bardoxolone Activates Cardiac Nrf2, Increases Antioxidant Expression and Lowers Arterial Pressure in Rats with Heart Failure

Andi Zhang,Changhai Tian,Lie Gao,Irving H. Zucker
DOI: https://doi.org/10.1096/fasebj.2018.32.1_supplement.903.11
2018-01-01
Abstract:Chronic heart failure (CHF) is associated with increased levels of oxidant stress in many tissues. High levels of reactive oxygen species (ROS) impairs cardiac, neural and renal function. Increased ROS in CHF is, in part, due to low levels of a variety of antioxidant enzymes. Many of these enzymes are regulated by the activity of the transcription factor Nuclear factor E2‐related factor 2 (Nrf2), which binds to antioxidant response elements (ARE) on multiple genes. Activation of Nrf2 has been shown to modulate a variety of disease states as well as several negative effects of the aging process. We hypothesized that pharmacological activation of systemic Nrf2 would provide beneficial hemodynamic effects in a rodent model of CHF. Male Sprague Dawley rats were subjected to left coronary artery ligation or sham surgery, and were divided into four groups (Sham+Vehicle, Sham+Nrf2 activator, CHF+Vehicle and CHF+Nrf2 activator) based on echocardiographic analysis 4 weeks post myocardial infarction. The Nrf2 activator, bardoxolone was administered daily for another 2 weeks by intraperitoneal injection (i.p) injection. Control animals were treated with the saline vehicle. Hemodynamics were evaluated by ventricular catheterization (Millar) and echocardiography (Vevo 2100). Animals were sacrificed, tissues taken and kept at −80 °C until analyzed. Our results demonstrated that Bardoxolone did not cause any changes in LV ejection fraction in either group (72.1±1.3 sham‐vehicle vs 73.0±1.2 sham‐bardoxolone; 32.9± 0.8 CHF‐vehicle vs 33.5±0.8 CHF‐bardoxolone). However, Bardoxolone significantly reduced LV systolic pressure and mean arterial pressure in CHF rats (LVSP; Vehicle 138.0±8.0 vs bardoxolone 117.0±3.9 mm Hg, p=0.04; MAP; Vehicle 97.8±2.9 vs bardoxolone 87.5±4.5 mm Hg, p=0.07). In addition, Bardoxolone had no effect on LVEDP or LV dp/dt max or min in rats with CHF. Molecular studies further revealed that In CHF rats Nrf2 mRNA was increased in the non‐infarcted areas of the heart by 2.5‐fold. Importantly, both mRNA and protein levels of NAD(P)H dehydrogenase [quinone] 1 (NQO1), a known target for Nrf2, was significantly increased by bardoxolone. Co‐IP experiments in skeletal muscle also showed that Bardoxolone reduced NF‐kB and increased Nrf2 binding to the CREB‐Binding Protein, respectively. These data suggest that activation of Nrf2 may provide beneficial antioxidant effects on cardiac muscle in CHF and reduces afterload. The mechanisms for the peripheral effects have not been determined.Support or Funding InformationSupported by PO1 HL 62222 and an APS summer undergraduate fellowshipThis abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
What problem does this paper attempt to address?